BioSpace News Archive

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its first quarter 2021 financial and operating results on Wednesday, May 5, 2021.

- Publication title: “An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits potent immunity after a single dose” - Publication to be available on pre-print server, bioRxiv , and has been submitted for scientific journal peer-review

IQVIA (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced Connected Intelligence™, its innovative approach to enabling life sciences customers to discover powerful new insights, drive smarter decision-making, and get treatments to patients faster.

Cognoptix, a leading medical device/diagnostics company dedicated to the early detection of Alzheimer’s disease (AD), announced today that Dr. Susanne Wilke , the Company’s President and Chief Executive Officer, will present a “Spotlight Showcase” of Cognoptix under the title “Early-Stage Detection of Alzheimer’s Disease

Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp., headlined Collision 2021 and discussed the changing landscape of beauty, health and wellness.

Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately.

Codex DNA, Inc., creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the release of a mRNA workflow for the BioXp™ workstation allowing scientists to generate synthetic mRNA from a DNA sequence in a single overnight run.

Just in time for summer, researchers have found how the natural super-antioxidant Pycnogenol® can safeguard your skin from seasonal changes and environmental stress.

Marrone Bio Innovations, Inc., an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, released an update letter to shareholders from Chief Executive Officer Kevin Helash.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, May 4, 2021 at 5pm ET to discuss its financial results and corporate update for the first quarter ended March 31, 2021.